BIOMARKERS FOR RAAS COMBINATION THERAPY

摘要

A method of predicting whether a subject having a cardiovascular, renal, and/or metabolic disease has an increased likelihood of benefiting from a combination treatment comprising at least two RAAS agents selected from renin inhibitors, ACEi and ARBs. This method comprises analysing a biological sample from the subject to determine the identity of the nucleotide pair at position -5312 of the renin gene, wherein the presence of a CC genotype at position -5312 indicates that the subject has an increased likelihood of benefiting from such a combination treatment.